A Phase 2, Randomized, Double-blind, Placebo-controlled Study of LMN-201 for Prevention of C. Difficile Infection Recurrence
Latest Information Update: 03 May 2024
At a glance
- Drugs LMN-Cdiff01 (Primary)
- Indications Clostridium difficile infections
- Focus Registrational; Therapeutic Use
- Acronyms REPREVE Trial
- Sponsors Lumen Bioscience
- 25 Apr 2024 Planned initiation date changed from 1 Mar 2024 to 19 Aug 2024.
- 17 Nov 2023 Planned initiation date changed from 1 Jan 2024 to 1 Mar 2024.
- 17 Oct 2023 According to a Lumen Bioscience media release,recruitment outreach beginning in Q4 2023.